Takeda Pharmaceutical (TAK) DIvidends Date & History

Key Takeaways

• Takeda Pharmaceutical (TAK) offers a forward dividend yield of approximately 4%, appealing for income seekers in the pharmaceutical sector.
• The company pays dividends semi-annually, with an annual target of 200 yen per ordinary share (around $0.66 for ADRs).
• Payout ratio exceeds 200% based on earnings, but free cash flow (FCF) of over $500 billion provides strong coverage.
• Progressive dividend policy aims to maintain or increase payouts annually, supported by robust cash generation.
• Compared to peers, TAK's yield is competitive, surpassing Johnson & Johnson (JNJ) and AbbVie (ABBV) but below Pfizer (PFE).
• Dividend sustainability looks favorable due to FCF strength, despite high earnings payout.

Dividend Overview

Takeda Pharmaceutical Company Limited (TAK), a leading global biopharmaceutical firm, maintains a progressive dividend policy committed to increasing or maintaining the annual dividend per share each year. The company distributes dividends semi-annually, with an FY2025 target of 200 yen per ordinary share—split into 100 yen interim and year-end payments—equating to roughly $0.66 annually for ADR holders at current exchange rates. This delivers a forward yield of about 4% at recent stock prices around $16.50. Takeda's profile positions it as a high-yield pharmaceutical stock rather than a rapid dividend growth contender, prioritizing reliable income alongside share buybacks to enhance shareholder returns. Payments are reliable, with the next ex-dividend date on September 30, 2025.

Dividend History and Growth

Takeda has upheld a consistent semi-annual dividend schedule, aligning with its progressive policy of at least maintaining payouts year-over-year. Recent ADR dividends include $0.339 in March 2025 and $0.322 in September 2025, contributing to a trailing twelve-month (TTM) payout around $0.50–$0.66. While not boasting a long streak of increases like some U.S. peers, the company has avoided cuts post its 2019 Shire acquisition, focusing on stability amid R&D investments. The policy supports modest growth potential, backed by core franchises in gastroenterology, oncology, and rare diseases. Over the past five years, yields have averaged 4.59%, reflecting resilience in a volatile sector.

Dividend Sustainability and Payout Ratio

Takeda's earnings-based payout ratio stands at approximately 279%, elevated due to TTM EPS of $0.23 and one-time acquisition impacts, raising flags on pure net income coverage. However, sustainability strengthens via cash flows: levered free cash flow (FCF) exceeds 536 billion yen TTM, yielding a cash payout ratio around 40–45%—well below 75% thresholds for concern. The company targets a 2x adjusted net debt to EBITDA ratio, maintaining investment-grade ratings. This FCF buffer, alongside projected FY2025 operating cash flows, supports ongoing dividends and R&D, mitigating risks from patent cliffs or currency fluctuations (yen depreciation aids ADR yields). Overall, financial stability favors continued payments.

Dividend Compared to Industry Peers

In the pharmaceutical industry, Takeda's ~4% yield outperforms conservative payers like Johnson & Johnson (JNJ) at ~2.3–2.5% and AbbVie (ABBV) at ~3.3%, while trailing high-yielders such as Pfizer (PFE) near 6.5% and Bristol-Myers Squibb around 4–5%. Merck (MRK) yields ~3%. TAK's semi-annual cadence and progressive stance offer a middle-ground appeal: higher than growth-focused peers but with similar FCF coverage to leaders. This positions it attractively for yield hunters versus lower-yielding aristocrats emphasizing rapid hikes.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover high-yield pharmaceutical plays like TAK.

Is This Stock Attractive for Dividend Investors?

Takeda Pharmaceutical (TAK) suits income-oriented investors prioritizing elevated yields over aggressive growth, particularly those comfortable with international exposure and semi-annual payouts. Its 4% yield exceeds many large-cap pharma peers, backed by substantial FCF despite a high earnings payout ratio, appealing to yield-focused portfolios seeking defensive healthcare allocation. Conservative dividend seekers may appreciate the progressive policy and buyback complementarity, offering stability amid R&D cycles and patent dynamics. However, growth investors might prefer U.S. Dividend Aristocrats like JNJ with longer increase streaks and lower ratios. Currency risk (yen/USD) and debt from past M&A (mergers and acquisitions) warrant monitoring, as does sector volatility from drug approvals. Balanced portfolios could view TAK as a yield enhancer, complementing lower-yield staples for diversified income.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations